These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 19563267)
1. The search for new COX-2 inhibitors: a review of 2002 - 2008 patents. Ramalho TC; Rocha M; da Cunha EF; Freitas MP Expert Opin Ther Pat; 2009 Sep; 19(9):1193-228. PubMed ID: 19563267 [TBL] [Abstract][Full Text] [Related]
2. Targeting inhibition of COX-2: a review of patents, 2002-2006. da Cunha EF; Ramalho TC; Josa D; Caetano MS; de Souza TC Recent Pat Inflamm Allergy Drug Discov; 2007 Jun; 1(2):108-23. PubMed ID: 19075973 [TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Ushiyama S; Yamada T; Murakami Y; Kumakura S; Inoue S; Suzuki K; Nakao A; Kawara A; Kimura T Eur J Pharmacol; 2008 Jan; 578(1):76-86. PubMed ID: 17920584 [TBL] [Abstract][Full Text] [Related]
6. Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. Okumura T; Sakakibara A; Murata Y; Kita Y Eur J Pharmacol; 2008 Jan; 578(1):97-9. PubMed ID: 17716650 [TBL] [Abstract][Full Text] [Related]
8. Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent. Somvanshi RK; Kumar A; Kant S; Gupta D; Singh SB; Das U; Srinivasan A; Singh TP; Dey S Biochem Biophys Res Commun; 2007 Sep; 361(1):37-42. PubMed ID: 17640617 [TBL] [Abstract][Full Text] [Related]
9. Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Gaziano JM; Gibson CM Am J Cardiol; 2006 May; 97(9A):23-9. PubMed ID: 16675319 [TBL] [Abstract][Full Text] [Related]
10. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. Urdaneta A; Siso A; Urdaneta B; Cardenas R; Quintero L; Avila R; Suarez-Roca H Brain Res Bull; 2009 Aug; 80(1-2):56-61. PubMed ID: 19463915 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. Dajani EZ; Islam K J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633 [TBL] [Abstract][Full Text] [Related]
12. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. Salinas G; Rangasetty UC; Uretsky BF; Birnbaum Y J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):98-111. PubMed ID: 17562780 [TBL] [Abstract][Full Text] [Related]
13. Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. Huntjens DR; Spalding DJ; Danhof M; Della Pasqua OE Eur J Pain; 2009 May; 13(5):448-57. PubMed ID: 18774319 [TBL] [Abstract][Full Text] [Related]
14. Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial. Luo C; He ML; Bohlin L Acta Pharmacol Sin; 2005 Aug; 26(8):926-33. PubMed ID: 16038624 [TBL] [Abstract][Full Text] [Related]
15. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. Patterson MK; Castellsague J; Walker AM Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705 [TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Arber N Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1852-7. PubMed ID: 18708371 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Gierse J; Nickols M; Leahy K; Warner J; Zhang Y; Cortes-Burgos L; Carter J; Seibert K; Masferrer J Eur J Pharmacol; 2008 Jun; 588(1):93-8. PubMed ID: 18457826 [TBL] [Abstract][Full Text] [Related]